Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a destructive inflammatory disease with limited therapeutic options. To better understand the inflammatory responses that precede and concur with collagen deposition, we used three models of pulmonary fibrosis and identify a critical mechanistic role for IL-17A. After exposure to bleomycin (BLM), but not Schistosoma mansoni eggs, IL-17A produced by CD4+ and γδ+ T cells induced significant neutrophilia and pulmonary fibrosis. Studies conducted with C57BL/6 il17a−/− mice confirmed an essential role for IL-17A. Mechanistically, using ifnγ−/−, il10−/−, il10−/−il12p40−/−, and il10−/−il17a−/− mice and TGF-β blockade, we demonstrate that IL-17A–driven fibrosis is suppressed by IL-10 and facilitated by IFN-γ and IL-12/23p40. BLM-induced IL-17A production was also TGF-β dependent, and recombinant IL-17A–mediated fibrosis required TGF-β, suggesting cooperative roles for IL-17A and TGF-β in the development of fibrosis. Finally, we show that fibrosis induced by IL-1β, which mimics BLM-induced fibrosis, is also highly dependent on IL-17A. IL-17A and IL-1β were also increased in the bronchoalveolar lavage fluid of patients with IPF. Together, these studies identify a critical role for IL-17A in fibrosis, illustrating the potential utility of targeting IL-17A in the treatment of drug and inflammation-induced fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17A increases and stabilizes TGF-βRII expression on fibroblasts, thereby enhancing their sensitivity to TGF-β120”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [120]
In the citing paper
“the functions of IL-17 include stimulation of ECM production, collagen disposition, and mediation of TGF-β signaling (144).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [144]
In the citing paper
“murine studies in which administration of IL-17A is sufficient to induce collagen accumulation and fibrotic lesions (144, 145)”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 6×
“More recently, studies have also suggested important inflammatory activities for TGF, with TGF providing an integral differentiation signal for the develop ment of proinflammatory IL17A–secreting cells (Bettelli et al., 2006; Veldhoen et al., 2006).”
BackgroundResultInfluentialCellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Self-citationIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 5×
“These observations also suggest that IL10 inhibits the development of BLMinduced fibrosis by targeting the proinflammatory IL23–IL17A pathway rather than the IL12–IFN axis.”
BackgroundInfluentialVeldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 3×
“However, recent studies demonstrated that TGF is also critically involved in the development of IL17A–producing lymphocytes (Bettelli et al., 2006; Veldhoen et al., 2006), which regulate the development of a variety of inflammatory and autoimmune diseases (Tesmer et al., 2008).”
BackgroundSutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553 · cited 3×
“Similarly, IL1 can stimulate IL17A production (Sutton et al., 2009), and IL1 is a critical mediator of pulmonary fibrosis (Gasse et al., 2007).”
BackgroundMcGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520 · cited 3×
“Similar to previ ous studies (McGeachy et al., 2007; Stumhofer et al., 2007), IL10 was often coexpressed with IL17A and RoRt, sug gesting that Th17 cells may develop into IL10–secreting cells to limit Th17 effector function.”
ResultInduction and effector functions of TH17 cells
Bettelli, E., Korn, T., Oukka, M., & Kuchroo, V. K. (2008) · Nature · doi:10.1038/nature07036 · Cited by 1,216 · cited 2×
“, 2006), which regulate the pathogenesis of a variety of autoimmune and inflammatory diseases (Bettelli et al., 2008).”
BackgroundTesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
Nakae, S., Komiyama, Y., Nambu, A., Sudo, K., Iwase, M., Homma, I., Sekikawa, K., Asano, M., & Iwakura, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00391-6 · Cited by 1,052 · cited 1×
“However, IL17A has been implicated in IL13– associated airway hyperreactivity (Nakae et al., 2002).”
BackgroundOrtiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019 · cited 1×
“These observations are consistent with studies that suggested IL10 could regulate the magnitude and effec tor function of Th17 responses (Fitzgerald et al., 2007; McGeachy et al., 2007; Chang et al., 2008).”
Result
Cited by
Items 501–600 of 751
Yamada, T., Nakashima, T., Masuda, T., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Miyamoto, S., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6169 · Cited by 13
“IL-17A has been associated with worsening of pulmonary fibrosis [18,21,29].”
BackgroundLuo, H., Yan, J., & Zhou, X. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02699-8 · Cited by 12
IL-22 Binding Protein Controls IL-22–Driven Bleomycin-Induced Lung Injury
Zhang, Z., Chakawa, M., Galeas‐Pena, M., Frydman, J. A., Allen, M. J., Jones, M., & Pociask, D. A. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.11.011 · Cited by 12
The role and mechanism of TXNDC5 in disease progression
Jiao, M., Zhang, Y., Xie, S., & Xu, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354952 · Cited by 13
Activation of Toll-like receptor 9 attenuates unilateral ureteral obstruction-induced renal fibrosis
Xin, B., Wang, X., Jin, W., Yan, H., Cui, B., Zhang, X., Hua, F., Yang, H., & Hu, Z. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.202 · Cited by 12
Elevated Interleukin‐17A expression in amlodipine‐induced gingival overgrowth
Sume, S. S., Berker, E., Ilarslan, Y. D., Yücel, Ö. Ö., Tan, Ç., Goyushov, S., Gültekin, S. E., & Tezcan, İ. (2020) · Journal of Periodontal Research · doi:10.1111/jre.12747 · Cited by 15
Fujisawa, Y., Matsuda, K., & Uehara, T. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0125 · Cited by 14
Nepon, H., Julien, C., Petrecca, S., Kalashnikov, N., Safran, T., Murphy, A. M., Dionisopoulos, T., Davison, P. G., & Vorstenbosch, J. (2024) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37762 · Cited by 12
Potential of Targeting TGF-β for Organ Transplant Patients
Iwashima, M., & Love, R. B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.215 · Cited by 11
El-Hak, H. N. G., Mohamed, O. E., & Nabil, Z. I. (2021) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2021.1977881 · Cited by 14
“It has been reported to induce significant functional and biochemical changes in addition to pulmonary fibrosis (Wilson et al. 2010), Bronchial metaplasia, aggressive macrophage recruitment, atypical alveolar epithelial cells, fibrinous edema, and interstitial fibrosis (Zaghloul et al. 2017).”
BackgroundFang, Q., Xie, J., Zong, J., Zhou, Y., Zhou, Q., Yin, S., Cao, L., Yin, H., & Zhou, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112173 · Cited by 12
Imbalance of dendritic cell function in pulmonary fibrosis
Yuan, Y. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156687 · Cited by 11
Jacobs, I., Deleu, S., Ke, B.-J., Cremer, J., Dilissen, E., Hertogh, G. D., Martens, T., Berghe, P. V., Matteoli, G., Vermeire, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-78602-0 · Cited by 12
The role of innate lymphoid cells in airway inflammation: evolving paradigms
Krohn, I. K., Bal, S. M., & Golebski, K. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000435 · Cited by 12
Ding, W. J., Zhang, X., PAN, M., Zhao, B., Chen, C., Niu, Z.-H., Huang, C.-L., LI, Y.-Y., FAN, X.-M., Ma, Y., et al. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2564 · Cited by 11
Magnolol reduces bleomycin-induced rodent lung fibrosis.
Zhang, X., Huang, H., Chang, H., & Jin, X. (2015) · PubMed · Cited by 12
Association between SNPs at IL-17A and IL-17F and susceptibility to accelerated silicosis
Hassani, E., Bagheri, M., Rad, I. A., & Mohebbi, I. (2017) · Toxicology and Industrial Health · doi:10.1177/0748233717695431 · Cited by 13
Role of a novel immune modulating DDR2-expressing population in silica-induced pulmonary fibrosis
McDonald, L. T., Johnson, S. D., Russell, D. L., Young, M. R., & LaRue, A. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180724 · Cited by 11
Autoimmune markers for progression of Libby amphibole lamellar pleural thickening
Pfau, J. C., McNew, T., Hanley, K., Swan, L., & Black, B. (2019) · Inhalation Toxicology · doi:10.1080/08958378.2019.1699616 · Cited by 13
“IL-1 beta drives TH17 responses and is part of the inflammasome pathway (Wilson et al. 2010; Biswas et al. 2011; Song et al. 2014).”
BackgroundRole of adipokines in systemic sclerosis pathogenesis
Frommer, K., Neumann, E., & Müller‐Ladner, U. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2020.19107 · Cited by 12
“IL-17 is another important cytokine in SSc, which has an effect on both inflammation (14) and fibrosis (15, 16).”
BackgroundThe involvement of HDAC3 in the pathogenesis of lung injury and pulmonary fibrosis
Yu, H., Liu, S., Wang, S., & Gu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392145 · Cited by 11
Zhao, X., Xia, H., Yang, Y., Ma, T., Lu, Y., Xie, Z., Zhou, X., Liu, J., Bao, Z., Xu, H., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.05.006 · Cited by 14
Mechanotherapy: Modulating immune cell function in tissue regeneration and fibrosis
Ward, N. A., Prendeville, H., Wallace, E. J., Shokrani, P., Trask, L., Dillon, R., Beatty, R., Roche, E. T., Duffy, G. P., & Dolan, E. B. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.048 · Cited by 11
Activation of the P2RX7/IL-18 pathway in immune cells attenuates lung fibrosis
Hreich, S. J. D., Juhel, T., Leroy, S., Ghinet, A., Brau, F., Hofman, V., Hofman, P. M., & Vouret‐Craviari, V. (2023) · eLife · doi:10.7554/elife.88138.4 · Cited by 10
Exploiting the potential of lung stem cells to develop pro-regenerative therapies
Hynds, R. E. (2022) · Biology Open · doi:10.1242/bio.059423 · Cited by 11
“, 1996) and IPF patients (Wilson et al., 2010), as well as tissue from COPD patients (Pauwels et al.”
BackgroundSalt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury
van Gijsel‐Bonnello, M., Darling, N. J., Tanaka, T., Carmine, S. D., Marchesi, F., Thomson, S. M., Clark, K., Kurowska‐Stolarska, M., McSorley, H. J., Cohen, P., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102644 · Cited by 12
Chioma, O. S., Mallott, E. K., Shah-Gandhi, B., Wiggins, Z., Langford, M., Lancaster, A. W., Gelbard, A. H., Wu, H., Johnson, J. E., LANCASTER, L. H., et al. (2023) · Cells · doi:10.3390/cells12050766 · Cited by 11
Surviving Pulmonary Tuberculosis: Navigating the Long Term Respiratory Effects
Bansal, A., Yanamaladoddi, V. R., Sarvepalli, S. S., Vemula, S. L., Aramadaka, S., Mannam, R., & Narayanan, R. S. (2023) · Cureus · doi:10.7759/cureus.38811 · Cited by 10
“IL-1β has been related to fibrosis in patients with IPF [26].”
BackgroundSandbo, N. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_8 · Cited by 13
Boin, F., & Chizzolini, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_13 · Cited by 10
IL-17A suppresses and curcumin up-regulates Akt expression upon bleomycin exposure
Gouda, M. M., Prabhu, A., & Bhandary, Y. P. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4199-3 · Cited by 10
Olivas-Flores, E. M. (2015) · World Journal of Rheumatology · doi:10.5499/wjr.v5.i1.1 · Cited by 10
Li, J., Mao, N., Wang, Y., Deng, S., & Chen, K. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.011 · Cited by 12
Effects of silver nanoparticles–polysaccharide on bleomycin-induced pulmonary fibrosis in rats
Hassan, A. I., Samir, A., Youssef, H. F., Mohamed, S. S., Asker, M. S., & Mahmoud, M. G. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab037 · Cited by 11
Disulfiram ameliorates bleomycin induced pulmonary inflammation and fibrosis in rats
Hamidi, N., Feizi, F., Azadmehr, A., Zabihi, E., Khafri, S., Zarei‐Behjani, Z., & Babazadeh, Z. (2023) · Biotechnic & Histochemistry · doi:10.1080/10520295.2023.2261367 · Cited by 11
“Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1 β), contribute to fibrosis of the lung (Wilson et al. 2010; Borthwick 2016).”
BackgroundCoronado, K., Herrada, C., & Rojas, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063150 · Cited by 9
A recombinant IL-1β vaccine attenuates bleomycin-induced pulmonary fibrosis in mice
Li, H., Li, Q., Hao, Z., Zhang, L., Zhang, L., Zhu, L., Huo, Y., Tian, H., He, L., & Hao, Z. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.091 · Cited by 10
Ran, Z., Mu, B., Zhu, T., Zhang, Y., Luo, J., Xiong, Y., Li, B., Wang, D.-M., & Lu, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112766 · Cited by 11
Enzel, D., Kriventsov, M. A., Sataieva, T., & Malygina, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168946 · Cited by 12
Shadid, A., Rich, H. E., DeVaughn, H., Domozhirov, A. Y., Doursout, M., Mills, T., Eckel‐Mahan, K. L., Karmouty‐Quintana, H., Restrepo, M. I., & Shivshankar, P. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1479801 · Cited by 10
Inflammasome in the Pathogenesis of Pulmonary Diseases
Xu, F., Wen, Z., Shi, X., & Fan, J. (2018) · Experientia supplementum · doi:10.1007/978-3-319-89390-7_6 · Cited by 9
“IL-1 beta was further reported sufficient to induce IL-17 production, required for inflammatory response to bleomycin (Wilson et al. 2010; Gasse et al. 2011).”
BackgroundChen, J., Jian, X., Li, C., & Cheng, B. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.114732 · Cited by 9
Pang, L., Ding, Z., Chai, H., & Shuang, W. (2023) · Open Medicine · doi:10.1515/med-2023-0877 · Cited by 9
Neveu, W. A., Staitieh, B. S., Mills, S. T., Guidot, D. M., & Sueblinvong, V. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14110 · Cited by 10
“Interleukin-17 (IL-17) has been shown to regulate fibroblast behavior in response to tissue damage, particularly in the bleomycin-induced lung injury rodent model (Park et al., 2018, Cipolla et al., 2017, Wilson et al., 2010).”
BackgroundWang, W., Liu, Z., Niu, J., Yang, H., Long, Q., Liu, H., Gu, X., & Jiao, Y. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/5814658 · Cited by 9
“Wilson and his colleagues [18] found that bleomycininduced lung fibrosis in mice depends on IL-17-related signaling pathways.”
BackgroundZhao, A., Unterman, A., Hussein, N. S. A., Sharma, P., Flint, J., Yan, X., Adams, T. S., Justet, A., Sumida, T. S., Zhao, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.20.558301 · Cited by 14
Yamada, S., Honzawa, Y., Yamamoto, S., Matsuura, M., Kitamoto, H., Okabe, M., Kakiuchi, N., Toyonaga, T., Kobayashi, T., Hibi, T., et al. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad259 · Cited by 8
M. S. Barron, A., Fabre, T., & De, S. (2024) · F1000Research · doi:10.12688/f1000research.143472.1 · Cited by 8
“72,309,323 326 Increased expression of IL-17A is associated with IPF, NASH and other fibrotic diseases while, to our knowledge, increased IL-22 has only been observed in NASH patients.”
BackgroundSouza, J. L. N., Amorim, C. C. O., Lopes, C. D. A., Vieira-Santos, F., Antunes-Porto, A. R., Souza, F. R., Oliveira, E. A., Vieira, T. C., Kraemer, L. R., Cardozo, M. E., et al. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00477 · Cited by 8
IL-21, not IL-17A, exacerbates murine primary biliary cholangitis
Chan, C.-W., Chen, H., Wang, Y., Lin, C., & Chuang, Y. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad107 · Cited by 9
Sung, E., Park, M. H., Song, S.-J., Alanya, H., Henegariu, O., Liu, J., Erson-Omay, Z., Sime, P. J., & Chae, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1247330 · Cited by 8
Morikka, J., Federico, A., Möbus, L., Inkala, S., Pavel, A., Sani, S., Vaani, M., Peltola, S. K., Serra, A., & Greco, D. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.10.010 · Cited by 9
“However, whilst the importance of macrophages and their cytokine signalling is well understood in the progression of PF, a comprehensive understanding of the mechanistic response of macrophages to profibrotic challenge is understudied.”
BackgroundVigeland, C. L., Collins, S. L., Chan‐Li, Y., Hughes, A. H., Oh, M. H., Powell, J. D., & Horton, M. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163288 · Cited by 10
Protective Effects of Morin Against Bleomycin-Induced Pulmonary Fibrosis in Mice
Hemmati, A. A., Pashmforosh, M., Tabandeh, M. R., Rezaie, A., Vardanjani, H. R., Pipelzadeh, M. H., & Karampour, N. S. (2019) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp.79624 · Cited by 10
“It is reported that BLM-induced weight loss is associated with lung inflammation (21).”
BackgroundRole of platelet factor 4 in arteriovenous fistula maturation failure: What do we know so far?
Xiao, Y., Vázquez-Padrón, R. I., Martinez, L., Singer, H. A., Woltmann, D., & Salman, L. H. (2022) · The Journal of Vascular Access · doi:10.1177/11297298221085458 · Cited by 8
Fine mapping of the major bleomycin-induced pulmonary fibrosis susceptibility locus in mice
Bergeron, M.-E., Stefanov, A. N., & Haston, C. K. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9774-3 · Cited by 8
Majd, A. M. M., Faghihzadeh, S., Pourfarzam, S., Eghtedardoost, M., Jamali, D., Mirsharif, E. S., Dilmaghanian, R., & Ghazanfari, T. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105828 · Cited by 9
Arai, T., Hirose, M., Kagawa, T., Hatsuda, K., & Inoue, Y. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1418 · Cited by 11
“Most of these cytokines have been associated with pulmonary fibrosis (13,15,16,34-37), Table 3 Univariate and multivariate Cox proportional hazard regression analysis to evaluated predictive factors of occurrence of acute exacerbation in IPF Parameters HR 95% CI P value”
BackgroundPerkins, J. B., Ravi, K., Guo, C., Oh, G. J., Rodriguez, B. G., Chen, C.-N., Jansons, S. I., Sun, F. C. S., Gurczynski, S. J., Weinberg, J. B., et al. (2026) · Science Advances · doi:10.1126/sciadv.adw4654 · Cited by 9
“IL-17, produced by T H 17 cells, drives chronic inflammation and fibroblast activation, contributing to tissue remodeling and fibrotic progression ( 16 , 57 – 59 ).”
Hermansky-Pudlak syndrome: Gene therapy for pulmonary fibrosis
Nieto-Alamilla, G., Behan, M., Hossain, M. S., Gochuico, B. R., & Malicdan, M. C. V. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.08.008 · Cited by 7
Self-citationThe aryl hydrocarbon receptor: A promising target for intestinal fibrosis therapy
Pan, Y., Deng, Y., Yang, H., & Yu, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107909 · Cited by 11
Macrophage polarization in adenomyosis: A review
Qiu, Y., Cao, J., Li, S., Liu, Y., Wan, G., & Gui, T. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13841 · Cited by 8
The Oral–Lung Microbiome Axis in Connective Tissue Disease-Related Interstitial Lung Disease
Bongers, K. S., Massett, A., & O’Dwyer, D. N. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1785673 · Cited by 7
Chronic rejection: a significant role for Th17-mediated autoimmune responses to self-antigens
Subramanian, V., & Mohanakumar, T. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.58 · Cited by 7
Cellular and Molecular Mechanisms of Chronic Inflammation-Associated Organ Fibrosis
Tsukui, T., Shichino, S., Shimaoka, T., Ueha, S., & Matsushima, K. (2016) · Springer eBooks · doi:10.1007/978-4-431-56068-5_2 · Cited by 7
Humoral Immunity and the Development of Obliterative Bronchiolitis after Lung Transplantation
Emtiazjoo, A. M., & Wilkes, D. S. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0349rt · Cited by 8
“In addition, nontransplant studies have reported that IL-17 is fibrogenic in the lung (54).”
BackgroundTan, J., Wu, X., Huang, W., He, J., Nie, J., Zhou, L., Liu, Z., Wang, Y., Liu, C., Li, J., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251391093 · Cited by 7
Sunitinib displays pulmonary fibrosis in experimental rats: Role of IL-17A dependent pathway
Asker, M. E.-S., Abdelmeged, A. A., Shaheen, M. A., & Eissa, R. G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110173 · Cited by 6
Sexual dimorphism of lung immune-regulatory units imprint biased pulmonary fibrosis
Peng, X. F., Wang, L., Xu, F., Guo, Q., Xie, G., Sheng, L., Chen, L., Teng, J., Yang, J., Wu, X., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01293-8 · Cited by 7
Osman, N. H., Jailani, R. F., Rahman, H. A., & Hamid, N. A. (2021) · Annals of Coloproctology · doi:10.3393/ac.2021.00584.0083 · Cited by 6
“More recent studies indicated that IL-17A might induce EMT on epithelial cells to indirectly promote fibrosis in multiple organs [34-38].”
BackgroundLiu, W., Zhang, J.-H., Gao, L., & Xiao, J. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114098 · Cited by 6
Zhao, Y., Yang, J., Zhang, Q., Chen, X., Liang, W., Zheng, Y., Huang, J., Liao, Y., Fu, C., Huang, T., et al. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.07.004 · Cited by 6
Wang, Y., Li, J., Chen, R., Xu, Q., Wang, D., Mao, C., Xiang, Z., Wu, G., Wu, G., Li, J., et al. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127930 · Cited by 8
Mohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 123
Review of Promising Off-Label Use of Deucravacitinib
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199447 · Cited by 7
Immunological mechanisms underlying fibrotic diseases via single-cell technologies
Koda, Y., Nakamoto, N., & Kanai, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1720047 · Cited by 6
Mahajan, S., Mahajan, S., & Gusain, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031391 · Cited by 6
“Persistent IL-17 signaling has been implicated in fibroblast activation and extracellular matrix deposition, suggesting a role in the development of pulmonary fibrosis and long-term lung impairment following severe COVID-19 [61].”
NKT Deficient Mice are not Spared Lung Disease after Exposure to Thoracic Radiotherapy
Paun, A., Bergeron, M.-E., & Haston, C. K. (2014) · Radiation Research · doi:10.1667/rr13581.1 · Cited by 5
Lan, Y., Chen, C.-E., Huang, T., Huang, T., Chen, C., & Chong, K. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100720 · Cited by 5
Moog, M., Baltes, M., Bormann, T., Aschenbrenner, F., Maus, R., Stolper, J., Jonigk, D. D., Prinz, I., Kolb, M. R. J., & Maus, U. A. (2024) · European Journal of Immunology · doi:10.1002/eji.202451323 · Cited by 5
“Bronchoalve-olar lavage (BAL) fluids of IPF patients display increased levels of IL-17A compared with healthy controls, and IL-17A-producing cells were found in active disease areas of IPF lungs [14, 15].”
Tukhovskaya, E. A., Palikova, Y. A., Severyukhina, M. S., Ismailova, A. M., Паликов, В. А., Слащева, Г. А., Borozdina, N. A., Mikhaylov, E. S., Kravchenko, I. N., Kazakov, V. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101360 · Cited by 5
Murthy, S., Seabold, D., Gautam, L. K., Caceres, A. M., Sease, R., Calvert, B. A., Busch, S. M., Neely, A., Marconett, C. N., & Ryan, A. L. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00293.2024 · Cited by 6
Bradley, J., OʼShea, P., Wrench, C., Mattsson, J., Paulin, R., Overed-Sayer, C. L., Rosenberg, L., Olsson, H., & Gianni, D. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100223 · Cited by 5
Greco, C. T., Akins, R. E., Epps, T. H. I., & Sullivan, M. O. (2017) · Advanced Biosystems · doi:10.1002/adbi.201700099 · Cited by 7
Liu, L., Yan, H., Wang, Y., Xie, Y., Jiang, L., Zhao, J., Gao, C., Li, X., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012513 · Cited by 5
A novel bispecific antibody alleviates bleomycin-induced systemic sclerosis injury
Yin, Q., Pi, X., Ren, G., Liu, Z., Liu, H., Wang, M., Hu, C., Zhao, H., Li, D., & Yin, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106644 · Cited by 5
Do inflammasome impact COVID-19 severity?
Calado, M. B., Santana, C. E. D. S., & Crovella, S. (2021) · VirusDisease · doi:10.1007/s13337-021-00705-3 · Cited by 8
Sbierski‐Kind, J., Cautivo, K. M., Wagner, J. C., Dahlgren, M. W., Nilsson, J., Krasilnikov, M., Mroz, N. M., Lizama, C. O., Gan, A. L., Matatia, P. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.26.537913 · Cited by 5
Novel Therapeutic Strategies Targeting Fibroblasts to Improve Heart Disease
Li, Y. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31504 · Cited by 4
“This promotes neutrophil activity, enhances the inflammatory response, and aggravates cardiac fibrosis (Wilson et al. 2010).”
The Intersection between Immune System and Idiopathic Pulmonary Fibrosis—A Concise Review
Liu, H., Cui, H., & Liu, G. (2025) · Fibrosis · doi:10.70322/fibrosis.2025.10004 · Cited by 7
“Additionally, direct targeting of Th17 cells by IL-17A knockout or the use of an anti-IL-17A antibody has been shown to decrease fibrosis [114,115].”
Jiawang, W., Liu, T., Zhang, X., Qu, C. F., Wu, J., Xu, S., Yang, J., & Xing, X. (2025) · Biofabrication · doi:10.1088/1758-5090/adde15 · Cited by 4
“Meanwhile, TGF-β secreted by macrophages is a central factor in fibrosis; it promotes the synthesis and deposition of ECM by activating the SMAD and ERK signaling pathways, leading to pulmonary tissue sclerosis [170, 171].”
Li, C., Wang, X., Tian, M., Zhang, M., Zhang, X., Fu, Q., Liu, L., Zhang, L., & Wang, H. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111428 · Cited by 5
Li, S., Li, Z., Yin, R., Nie, J., Fu, Y., & Ying, R. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105902 · Cited by 4
Effect of anti‐interleukin‐17 biologics on Krebs von den Lungen‐6 level in patients with psoriasis
Hara, H., Miyagawa, H., Araya, J., Minagawa, S., Numata, T., Umezawa, Y., Asahina, A., Nakagawa, H., & Kuwano, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15895 · Cited by 4
Lee, W. J., Li, W. Y., Lee, S.-W., & Jung, S. K. (2021) · Applied Sciences · doi:10.3390/app11104711 · Cited by 4
“is of particular interest as inflammatory cytokines can cause systemic inflammation [39] and, particularly, IL-1β causes a fibrosis reaction and an acute inflammatory reaction in the lungs [40,41].”
BackgroundKozhin, P. M., Владимирович, Ч. А., Сергеевна, З. Н., Валерьевна, Х. М., Александровна, Ч. Л., Брониславовна, М. Е., Васильевич, Т. А., & Алексеевич, Ш. В. (2019) · Сибирский научный медицинский журнал · doi:10.15372/ssmj20190403 · Cited by 4
Chen, Y., Liu, F., Weng, D., Song, L., Li, C., Tang, W., Yu, Y., Dai, W., & Chen, J. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711784 · Cited by 5
“IL-1β-mediated inflammation and fibrosis is dependent on IL-17 (Wilson et al., 2010).”
BackgroundCeballos‐Santa, M. C., Babu, J. V., Gaborski, T. R., Schulze, S., & Wuertz‐Kozak, K. (2026) · Advanced Biology · doi:10.1101/2025.06.17.660207 · Cited by 3
Lee, D., Kong, B., Kwak, G., Kang, B., Swaby, C., Fanaroff, R. E., Sidhaye, V. K., & Suk, J. S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01973-y · Cited by 4
Sbierski‐Kind, J., Cautivo, K. M., Nilsson, J., Wagner, J., Dahlgren, M. W., Ewing-Crystal, N. A., Krasilnikov, M., Mroz, N. M., Ganslmeier, M., Lizama, C. O., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea6805 · Cited by 3
Metadata
- Authors
- Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A.
- Affiliations
- National Institutes of Health (US)
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 3
- Biomedical Research Institute (US)
- Corresponding author
- Wynn, Thomas A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-02-22
- Volume
- 207
- Issue
- 3
- Pages
- 535-552
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2839145
- OpenAlex
- W2095715691
- Cited by
- 730
- References
- 84
- Citations by year
- 2026: 28 · 2025: 39 · 2024: 68 · 2023: 45 · 2022: 47 · 2021: 39 · 2020: 38 · 2019: 51 · 2018: 47 · 2017: 48 · 2016: 42 · 2015: 42 · 2014: 40 · 2013: 57 · 2012: 45
- FWCI
- 41.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, IL-17A, bleomycin-induced lung injury, IL-1β, pulmonary fibrosis, TGF-beta, IL-10, interferon-gamma, IL-12/23p40, γδ T cells, CD4+ T cells, neutrophilia, Schistosoma mansoni eggs, bronchoalveolar lavage, IL-17A blockade
- MeSH terms
- Animals, Bleomycin, Interferon-gamma, Lung, Male, Mice, Inbred C57BL, Pulmonary Fibrosis, Schistosoma mansoni, Schistosomiasis mansoni, CD4-Positive T-Lymphocytes, Interleukin-10, Mice, Knockout, Interleukin-13, Interleukin-17, Mice, Interleukin-1beta, Interleukin-12 Subunit p40
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.